Is Hormone Replacement Therapy Safe? Understanding the Risks and Benefits

A major FDA labeling change reflects how the HRT conversation has evolved

One of the biggest changes in the menopause hormone therapy conversation came recently.

In November 2025, the FDA asked manufacturers to revise menopausal hormone therapy labeling. In February 2026, the agency approved revised labeling for an initial group of products.

In a major change, the FDA removed statements about cardiovascular disease, breast cancer, and probable dementia from the boxed warning—often called the “black box warning” by patients and the public.

The boxed warning is the FDA's most prominent safety-related warning format, so changing it after more than two decades is significant.

It does not mean hormone therapy has no risks.

It means those risks should not be presented as though every woman, every age, every formulation, and every route of hormone therapy carries the same risk.

That is an important distinction—and it reflects how much more individualized the HRT conversation has become.

The HRT used in the WHI is not the only HRT available today

To understand why the conversation changed, it helps to understand what researchers actually studied in the Women's Health Initiative, or WHI.

The terminology can make the treatment used in that study sound more similar to many current hormone regimens than it actually was.

The estrogen used in the major WHI trials was conjugated equine estrogen, usually shortened to CEE.

CEE is a mixture of several estrogens originally derived from horses.

In women who still had a uterus, that estrogen was paired with medroxyprogesterone acetate, or MPA, a synthetic progestin.

Today, many women are prescribed different hormones and delivery methods.

For example, FDA-approved forms of estradiol are available as patches, gels, sprays, and oral medications. Estradiol is chemically identical to the primary estrogen produced by the ovaries.

FDA-approved micronized progesterone is likewise chemically identical to the progesterone produced by the body.

These are examples of bioidentical hormones.

And this distinction is important:

Bioidentical does not mean compounded.

FDA-approved estradiol and micronized progesterone are bioidentical hormone therapies.

Custom-compounded hormone products are a separate category. They do not undergo the same FDA review for dose consistency, purity, safety, and effectiveness as FDA-approved products.

Understanding those differences matters before applying findings from one older hormone combination to every form of HRT available today.

The benefits of HRT go beyond simply making menopause less miserable

Symptom relief matters enormously.

A woman who stops waking several times a night drenched in sweat may sleep better, think more clearly, function better at work, have more energy to exercise, feel less irritable, and simply feel more like herself.

That is a real improvement in quality of life.

But hormone therapy also has important physiologic benefits.

It is the most effective treatment for hot flashes and night sweats

Systemic estrogen remains the most effective treatment for vasomotor symptoms such as hot flashes and night sweats.

Reducing those symptoms can decrease the overall symptom burden that affects sleep, energy, concentration, mood, and daily functioning.

It helps protect bone

Estrogen loss accelerates bone loss around menopause.

Systemic hormone therapy helps prevent that bone loss and helps protect against osteoporosis while treatment is being used.

That matters because bone health is not simply a menopause symptom.

Loss of bone strength can affect mobility, fracture risk, and independence years later.

It can support vaginal and urinary health

Estrogen also affects the vulva, vagina, urethra, and bladder.

Hormone treatment can improve vaginal dryness and other symptoms of genitourinary syndrome of menopause, depending on whether systemic or local treatment is appropriate.

Timing may matter for cardiovascular health

The cardiovascular story is much more nuanced than “HRT causes heart disease.”

Age, baseline health, route of treatment, and how close a woman is to menopause all matter.

Current evidence supports a more favorable cardiovascular benefit-risk profile when hormone therapy is started in appropriately selected women before age 60 or within about 10 years of menopause.

That does not mean HRT should be prescribed solely to prevent cardiovascular disease.

It means the cardiovascular discussion depends heavily on who is being treated and when treatment begins.

The take-home point is that HRT is not only about surviving hot flashes. Appropriate hormone therapy can reduce symptom burden, improve quality of life, and help protect tissues and systems affected by estrogen loss.

So what did the Women's Health Initiative actually teach us?

The WHI was important research.

But it should be understood in context rather than used as shorthand for “HRT is dangerous.”

The women enrolled in the original trials were, on average, in their early 60s, and the study evaluated specific hormone preparations—CEE alone or CEE combined with MPA.

The results taught us that age, timing, formulation, and whether estrogen is used alone or with a progestogen matter.

That lesson remains important today.

What has changed is the idea that one study of particular regimens should define the risk of every form of menopause hormone therapy for every woman.

Breast cancer risk is not the same for every HRT regimen

Breast cancer is understandably one of the biggest concerns women bring to an HRT consultation.

The answer deserves more precision than simply saying:

“HRT increases breast cancer risk.”

The Menopause Society's current guidance notes that breast-cancer risk does not increase appreciably with short-term estrogen-progestogen therapy and may be decreased with estrogen-only therapy.

With combined estrogen-progestogen therapy, duration matters and breast-cancer risk becomes a more important part of the conversation with longer use.

The specific combination studied in the WHI was CEE plus MPA.

Those findings are important, but they should not automatically be treated as though every estrogen and every progestogen used today have an identical risk profile.

The type of progestogen may matter as well.

Observational research suggests that micronized progesterone may have a more favorable breast-cancer risk profile than some synthetic progestins, although long-term randomized comparisons of modern regimens are more limited.

That distinction is important because micronized progesterone is commonly used in contemporary menopause care and is not the same medication as the MPA used in the WHI combined-therapy arm.

The more accurate breast-cancer conversation considers:

• whether estrogen is used alone or with a progestogen
• which progestogen is used
• how long treatment is used
• the woman's baseline breast-cancer risk
• her age and timing of treatment
• her personal and family history

Breast-cancer risk deserves to be discussed, but it should be discussed in the context of the actual treatment being considered—not simply attached to the word “HRT.”

Why does having a uterus matter?

This is a separate issue from breast-cancer risk.

If you still have a uterus and use systemic estrogen, the uterine lining needs protection.

Estrogen by itself can stimulate that lining and increase the risk of endometrial cancer.

That is why women with a uterus generally receive a progestogen along with systemic estrogen.

Women who have had a hysterectomy generally do not need that endometrial protection and may be able to use estrogen alone.

So the uterus question determines whether progesterone or another progestogen is needed to protect the endometrium.

The breast-cancer question is a separate discussion about the long-term risk profile of the hormone regimen being used.

Route matters too: a patch is not the same as a pill

Another major evolution in hormone therapy is greater attention to how estrogen is delivered.

Oral estrogen travels through the liver before reaching the general circulation.

Transdermal estradiol—delivered through a patch, gel, or spray—bypasses that first-pass liver effect.

That matters particularly for blood-clot risk.

ACOG notes that oral estrogen may have a prothrombotic effect, while transdermal estrogen appears to have little or no effect on several clotting-related markers.

The Menopause Society also notes that blood-clot risk may be lower with transdermal estrogen than with oral estrogen.

This is another reason “HRT” should not be treated as one medication.

The hormone, dose, route, and progestogen can all change the risk-benefit conversation.

Who still needs a more cautious HRT discussion?

Modern hormone therapy is not appropriate for everyone.

A personal history of hormone-sensitive cancer, previous blood clots, stroke, significant cardiovascular disease, liver disease, unexplained vaginal bleeding, and other conditions may change the recommendation or require more specialized evaluation.

But risk assessment should help women find the treatment that fits them—not simply create another reason to dismiss their symptoms.

A family history of breast cancer, for example, is not the same thing as having personally had hormone-sensitive breast cancer.

Those details matter.

The goal is not to search for a reason to say no to HRT.

It is to understand the woman's individual risk profile well enough to make a thoughtful treatment decision.

What does this mean for a woman considering HRT today?

It means the conversation has changed substantially.

For an otherwise healthy woman in her 40s or 50s with disruptive menopause symptoms, the question should not begin with:

“How do we avoid hormones?”

It should begin with:

“What are my symptoms, what do I want to improve, and what treatment gives me the best balance of benefit and risk?”

For many women, HRT may be that treatment.

The Menopause Society's current position is clear that hormone therapy remains the most effective treatment for vasomotor symptoms and that, for most healthy symptomatic women younger than 60 or within 10 years of menopause onset, the benefit-risk ratio is favorable.

That does not mean every woman should take HRT.

It does mean women should not be unnecessarily frightened away from an effective treatment by an oversimplified interpretation of research performed more than two decades ago.

Want to understand whether HRT could be a good fit for you?

A menopause consultation gives you time to review your symptoms, medical history, medications, goals, and recent labs with a nurse practitioner and discuss the benefits, risks, formulation, and route that may make sense for you.

Explore Menopause Care

Where purelyIV fits

At purelyIV, menopause care begins with a 60–75 minute nurse practitioner consultation.

We review the symptoms affecting your life, your menstrual and medical history, medications, goals, existing labs, and the factors that influence treatment safety.

Before starting systemic HRT, we generally want to review recent baseline labs, and your NP may recommend updated testing when appropriate.

The discussion is not simply:

“Can you take HRT?”

It is:

“If hormone therapy makes sense for you, what approach fits you best?”

That may include decisions about estrogen route, whether progesterone is needed, dosing, symptom priorities, follow-up, or whether another treatment option is more appropriate.

The bottom line

The modern evidence around hormone therapy is more reassuring than many women realize.

HRT is the most effective treatment available for many menopause symptoms, can meaningfully reduce symptom burden and improve quality of life, and helps protect against menopause-related bone loss and osteoporosis.

For many healthy women who begin treatment before age 60 or within about 10 years of menopause, the overall benefit-risk profile is favorable.

And the FDA's recent labeling changes reflect an important evolution in how those risks are communicated:

Hormone therapy should not be treated as one drug with one universal risk profile.

Age matters.

Timing matters.

The type of estrogen matters.

The route matters.

The progestogen matters.

Your health history matters.

And your quality of life matters too.

The question is no longer simply:

“Is HRT safe?”

It is:

“What are the benefits and risks for me—and what treatment gives me the best chance to feel well now while protecting my long-term health?”

For the broader path through perimenopause, symptoms, testing, treatment options, safety, and follow-up, visit our Menopause & Perimenopause Guide.

Ready to have that conversation?

purelyIV menopause care starts with a 60–75 minute NP consultation to review your symptoms, health history, medications, goals, and recent labs before deciding what treatment approach fits your needs.

Schedule a Menopause Consult Explore Menopause Care & Memberships